Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

4P - Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing


06 Mar 2023


Cocktail & Poster Display session


Edwin Lin


Annals of Oncology (2023) 8 (1suppl_2): 100899-100899. 10.1016/esmoop/esmoop100899


E. Lin1, Y. Lo1, K. Parikh2, N. Smrecek3, K. Goliwas4, J. Deshane4, B. El-Rayes5, A. Desai6

Author affiliations

  • 1 Pathology, Mayo Clinic - Rochester, 55905 - Rochester/US
  • 2 Oncology, Mayo Clinic - Rochester, 55905 - Rochester/US
  • 3 Anesthesiology, Mayo Clinic - Rochester, 55905 - Rochester/US
  • 4 Medicine, The University of Alabama at Birmingham, 35294 - Birmingham/US
  • 5 Hematology And Oncology, The University of Alabama at Birmingham, 35294 - Birmingham/US
  • 6 Oncology, Mayo Clinic, 55901 - Rochester/US


This content is available to ESMO members and event participants.

Abstract 4P


Antibody-drug conjugates (ADCs), composed of monoclonal antibodies linked to cytotoxic drugs, are currently approved and standard-of-care for many malignancies including primary lung adenocarcinoma (LUAD). With several ADCs targeting different tumor antigens currently in clinical trials, it is important to characterize ADC targets to optimize drug development for LUAD.


RNA-sequencing data for 537 primary LUAD and 59 normal lung tissue samples were obtained from The Cancer Genome Atlas. Profiles of ADC-targetable gene expression including ERBB2 (HER2), ERBB3 (HER3), TACSTD2 (Trop2), MET (c-Met), CEACAM5, CD276 (B7-H3) and NECTIN4 within each tumor were assessed by comparison of transcripts per million. Recurrent patterns of ADC-targetable gene expression profiles were identified by hierarchical clustering. Differential gene expression was performed using the DESeq2 software package.


Differential gene expression analysis demonstrated higher expression of CEACAM5 (P=3.72E-53), TACSTD2 (P=9.62E-4) and MET (P=8.06E-10) in tumors compared to normal lung tissue. Interestingly, TACSTD2 (Trop-2) expression was inversely correlated with CEACAM5. On hierarchical clustering, we identified four distinct clusters based on ADC-targetable gene expression profiles: (1) CEACAM5 high/TACSTD2 low, (2) CEACAM5 low/TACSTD2 high, (3) MET high, (4) CEACAM5 mid/TACSTD2 mid. A subset of tumors had high expression of either CD276, ERBB2, or ERBB3; these tumors also had low expression of TACSTD2, CEACAM5, and MET.


In primary LUAD, CEACAM5, TACSTD2 and MET are significantly overexpressed in distinct segregable patterns. Particularly, CEACAM5 and TACSTD2 expression showed an inverse correlation and appeared to be nearly mutually exclusive biomarkers. This emphasizes the need for biomarker-based approaches for optimal selection of ADCs based on expression of target antigens.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


A. Desai: Financial Interests, Personal, Advisory Board: Amgen, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.